Supplementary Data from Immuno-oncological Efficacy of RXDX-106, a Novel TAM (TYRO3, AXL, MER) Family Small-Molecule Kinase Inhibitor

<p>Included are additional material and methods, biochemical and functional data demonstrating target specificity and engagement, flow cytometry gating strategies, histograms, and analyses, and TME cytokine data.</p>